Amarin - AMRN Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last twelve months. There are currently 2 sell ratings, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" AMRN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMRN, but not buy additional shares or sell existing shares.
View AMRN analyst ratings or view top-rated stocks.

6 equities research analysts have issued 12 month target prices for Amarin's stock. Their AMRN share price forecasts range from $1.50 to $3.00. On average, they predict the company's stock price to reach $2.38 in the next year. This suggests a possible upside of 54.7% from the stock's current price.
View analysts price targets for AMRN or view top-rated stocks among Wall Street analysts.

Amarin's stock was trading at $1.21 at the beginning of 2023. Since then, AMRN stock has increased by 26.9% and is now trading at $1.5350.
View the best growth stocks for 2023 here.

Amarin saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 18,890,000 shares, an increase of 30.1% from the February 28th total of 14,520,000 shares. Based on an average daily volume of 4,650,000 shares, the days-to-cover ratio is presently 4.1 days.
View Amarin's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our AMRN earnings forecast.

Amarin Co. plc (NASDAQ:AMRN) announced its earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.03) EPS for the quarter, topping analysts' consensus estimates of ($0.04) by $0.01. The biopharmaceutical company had revenue of $142 million for the quarter, compared to analyst estimates of $161.29 million. Amarin had a negative net margin of 28.66% and a negative trailing twelve-month return on equity of 17.60%. The business's quarterly revenue was down 8.5% compared to the same quarter last year. During the same period last year, the firm posted ($0.02) EPS.

ETFs with the largest weight of Amarin (NASDAQ:AMRN) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS), Global X Aging Population ETF (AGNG) and Invesco Nasdaq Biotechnology ETF (IBBQ).ProShares Ultra Nasdaq Biotechnology (BIB).

Amarin issued an update on its fourth quarter 2022 earnings guidance on Tuesday, January, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $88.00 million-$90.00 million, compared to the consensus revenue estimate of $86.92 million.

43 employees have rated Amarin Chief Executive Officer John Thero on Glassdoor.com. John Thero has an approval rating of 93% among the company's employees. This puts John Thero in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at Amarin to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amarin investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), Alibaba Group (BABA), Tesla (TSLA), Bank of America (BAC), Netflix (NFLX) and Novavax (NVAX).

Amarin trades on the NASDAQ under the ticker symbol "AMRN."

Amarin's stock is owned by many different retail and institutional investors. Top institutional shareholders include Morgan Stanley (5.45%), Millennium Management LLC (1.71%), SCP Investment LP (1.61%), Sarissa Capital Management LP (1.19%), Two Sigma Investments LP (1.03%) and ExodusPoint Capital Management LP (0.63%). Insiders that own company stock include David M Stack, John F Thero, Joseph S Zakrzewski, Michael Wayne Kalb, Olsen Per Wold and Steven B Ketchum.
View institutional ownership trends.

Shares of AMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AMRN stock can currently be purchased for approximately $1.54.

Amarin (NASDAQ:AMRN) has a market capitalization of $619.88 million and generates $369.19 million in revenue each year. The biopharmaceutical company earns $-105,800,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis.

The company employs 560 workers across the globe.

Amarin's mailing address is 77 Sir John Rogerson`s Quay Block C Grand Canal Docklands, Dublin L2, Dublin 2. The official website for the company is www.amarincorp.com. The biopharmaceutical company can be reached via phone at (531) 669-9020 or via email at investor.relations@amarincorp.com.